Mpox clinical and epidemiological patterns in the Central African Republic: a systematic review and meta-analysis

Fabrice Zobel Lekeumo Cheuyem[1,*], Davy Roméo Takpando-le-grand[2], Chabeja Achangwa[3], Lionel Berthold Keubou Boukeng[4,5], Solange Dabou[6], Henri Donald Mutarambirwa[7], Raissa Katy Noa Otsali[4], Ariane Nouko[1], Michel Franck Edzamba[1], Martine Golda Mekouzou Tsafack[1], Armel Evouna Mbarga[5], Georges Nguefack-Tsague[1]

[1] Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé 1, Yaoundé, Cameroon

[2] Field Coordinator of Frontline Field Epidemiology Training Program, Bangui, Central African Republic

[3] Department of Public Health, Faculty of Medical Sciences, University of West Indies, Bridgetown, Barbados

[4] Direction of Disease, Epidemics and Pandemics Control, Ministry of Public Health, Yaoundé, Cameroon

[5] Department of Public Health and Social Sciences, Faculty of Medicine and Pharmaceutical Sciences of Sangmelima, University of Ebolowa, Ebolowa, Cameroon

[6] Division of Health Policy and Research, Nkafu Policy Institute, Denis and Lenora Foretia Foundation, Yaoundé, Cameroon

[7] Migration Health Assessment Center (MHAC), International Organization for Migration, Yaoundé, Cameroon

[8] Direction of Disease, Epidemics and Pandemics Control, Ministry of Public Health, Yaounde, Cameroon.

*Corresponding author's address:

E-mail: zobelcheuyem@gmail.com

Tel: +237 696 57 28 07

Abstract

Background: Mpox remains a critical public health challenge in Central Africa, where endemic circulation of the virulent Clade I virus persists through zoonotic and human-to-human transmission. This systematic review and meta-analysis synthesize 40 years of evidence (1984-2024) to characterize Mpox epidemiology, vaccination gaps and clinical pattern in the Central African Republic (CAR), informing targeted control strategies for this re-emerging threat.

Methods: Following PRISMA guidelines, we conducted a comprehensive search of PubMed, ScienceDirect, Cochrane Library, and Scopus for studies reporting laboratory-confirmed Mpox cases in CAR. Pooled estimates were calculated using random/fixed-effects models with R Statistics version 4.4.2 with subgroup analysis conducted for period, region, participants and disease burden. Heterogeneity (I^2) and publication bias (funnel plots, Egger's and Begg's tests) were rigorously assessed. The confidence intervals (CIs) were estimated at 95% level of confidence.

Results: Among 15 included studies representing 1984-2024 surveillance data, the pooled severity rate was 60.9% (95%CI:47.5-72.8) - highest in Health Region 6 (77.3%, 95%CI: 55.6-90.2). The Case fatality rate (CFR) among confirmed cases was 10.9% (95% CI: 5.9-19.0). There was non-significant decrease in CFR from 11.5%; (95% CI: 6.1-20.7) before 2022 to 7.14% (95% CI: 0.7-1.9) from 2022 on. There was a persistent post-2022 CFR elevations in high-burden areas (13.5% for >10 cases). Higher mortality was observed in Eastern Health Regions (11.11%; 95% CI: 5.08-22.60) compared to Western Health Regions with no reported death. Among suspected cases, the CFR was 10.7% (95%CI: 6.6-17.0). Vaccination uptake was low (20.0%, 95%CI: 10.3-35.2). The clinical profile included fever (91.1%, 42.9-99.3), rash (85.5%, 95%CI: 75.7-91.8), lymphadenopathy (57.0%, 95%CI: 34.3-77.1). Severe manifestations like hemorrhagic lesions (22.2%) and mucosal involvement (oral:59.2%; genital:57.4%) were also reported.

Conclusion: The CAR faces a disproportionate Mpox burden characterized by high severity, elevated mortality, and suboptimal vaccine coverage, particularly in eastern regions. These findings suggest the urgent need for: (1) enhanced surveillance systems with genomic sequencing capacity; (2) prevention of disease lethality through early case detection and appropriate care provision; (3)

strengthening vaccine distribution prioritizing high-risk populations; and (4) context-specific interventions, including community education and healthcare worker training, to curb future outbreaks.

Keywords: Mpox, severity, case fatality, vaccination, clinical manifestation, signs and symptoms, systematic-review, meta-analysis, Central African Republic

Background

Mpox, formerly known as monkeypox, is an infectious viral disease caused by the monkeypox virus [1]. In 2022, the World Health Organization (WHO) declared Mpox a Public Health Emergency of International Concern for the second time, confirming its continued threat to global health security and underscoring the persistent risks posed by the disease [2]. As of May 2025, a total of 133 countries globally have notified 142,151 confirmed Mpox cases with 328 deaths, yielding a case fatality rate (CFR) of 0.09% [3].

By June 2025, several African countries have reported community transmission of mpox due to clade Ib monkeypox virus in the past six weeks [4]. These include Burundi, the Democratic Republic of the Congo, Ethiopia, Kenya, Malawi, Rwanda, South Sudan, Tanzania, Uganda, and Zambia, all of which are experiencing ongoing human-to-human transmission of the virus. The Democratic Republic of the Congo continues to report the highest number of confirmed mpox cases in Africa in 2025 [5]. Mpox was first identified in the DRC, but since then, it has spread to nearby non-endemic African nations [6]. Such countries include the Central African Republic (CAR) and the Republic of the Congo, where investigations have provided evidence of sustained community transmission [7,8].

To adequately respond to this community transmission, the CAR health authorities' response to this public health threat should rely on solid surveillance and healthcare systems prepared to detect, diagnose, and promptly manage all notified cases to avoid preventable deaths in-hospital or within the community [9]. This is a significant challenge, as the complexity and severity of disease outbreaks are placing a heavy burden on under-resourced health systems like CAR's. In addition, marginalized and hard-to-reach populations, such as refugees, internally displaced persons, nomadic

population and migrants, frequently encounter significant obstacles in accessing healthcare. This lack of access increases their susceptibility to this reemerging disease [10].

The Central African Republic's (CAR) situation regarding this outbreak is particularly sensitive due to its socioeconomic and political condition. The country is one of the least developed globally, with decades of political instability, armed conflict, and widespread displacement severely impacting its socio-economic status [11]. This has led to high levels of poverty, food insecurity, and a significant proportion of the population living in precarious conditions, often with limited access to basic amenities like clean water and sanitation [12]. These socio-economic vulnerabilities can exacerbate disease transmission and hinder effective public health responses, as communities often rely on traditional healers and informal healthcare providers. This reliance can delay diagnosis and appropriate management of infectious diseases like Mpox [13,14]. In this case, prevention remains one of the key strategies to control the spread of the disease within hotspots and across the country.

The implementation of Mpox vaccination activities could be an effective way to respond to this outbreak by vaccinating populations most at risk of contracting Mpox [15,16]. This includes individuals living in close proximity to wildlife reservoirs, particularly in forested, rural, and remote areas that experience a severe shortage of qualified health personnel, medical supplies, and diagnostic capabilities [8].

Most previous studies on Mpox in CAR were conducted with small sample sizes, thereby limiting the generalizability of their findings across the country [8,17–19]. Understanding the evolution of this disease and its regional distribution in this intricate setting is essential for designing and implementing effective Mpox prevention and control strategies tailored to the realities of the CAR. Therefore, this study aimed to provide insight into the epidemiological and clinical profile of the multiple Mpox outbreaks reported in CAR.

Methods

Study design

This is the first systematic review and meta-analysis providing insight on the clinical and epidemiological profile of Mpox in CAR from 1984 to 2024. It was reported based on the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines [20].

Article searching strategy

Literature searches were performed on PubMed, ScienceDirect, Cochrane Library, and Scopus to identify published research. The search approach involved the title and abstract screening of each study. A synthesis of keywords and Medical Subject Headings (MeSH) vocabulary was utilized, employing Boolean logic operators to narrow the search for each database used (Additional File 1, Supplementary Table 2). To ensure thoroughness, a supplementary manual searching was conducted to identify additional relevant publications not found in electronic databases. Additionally, the reference lists of included studies were reviewed to identify further relevant articles. Literature search was concluded on February 27, 2025.

Study setting

The CAR is a landlocked nation situated in the heart of Africa, with an estimated population of 6 million inhabitants in 2024 [21]. Most of its population (62%) lives in rural areas, with women being the most represented (50.9%). The country covers an area of 623,000 km² and is bordered to the North by Chad, to the East by South Sudan and the Republic of Sudan, to the South by the Democratic Republic of Congo and the Republic of Congo, and to the West by Cameroon [22]. Administratively, the country is divided into seven Health Regions, 20 Divisions, 85 Sub-divisions, 177 Councils, and around 8,302 villages. The capital, Bangui, has 10 Sub-divisions [23]. The CAR is characterized by diverse geographical features, ranging from dense rainforests in the south to savanna and semi-arid zones in the north [24]. This varied landscape, coupled with a predominantly rural population, influences human-animal interactions.

Eligibility criteria

This systematic review and meta-analysis encompassed all peer-reviewed published reports, regardless of study type or design, which documented Mpox in CAR. We excluded studies without clearly defined outcome variables. Duplicate articles were identified by title and abstract screening and subsequently removed prior to data extraction. Only articles published in English or French were included, and no temporal restrictions were applied to the publication date.

Data extraction

A structured Microsoft Excel 2016 form was used to collect data from all included articles. The data extraction checklist included the first author's name, study year, region, study design, setting, number

of suspected, confirmed, severe, and death cases, the number of individuals who received the Mpox vaccine, sample size, and the number of events of each clinical manifestation. Two authors independently assessed each article for quality and relevance. Discrepancies between reviewers were resolved through discussion with a third reviewer to achieve consensus.

Data quality assessment

The quality of included studies was assessed using the Joanna Briggs Institute quality assessment tool for case reports, case series generated following outbreak surveillance and investigations activities [25]. Risk of bias was evaluated using eight to ten criteria, depending on the study design. A binary score of 0 (no or unclear) or 1 (yes) was given after evaluation of each criterion. The overall risk of bias was categorized as low (>50%), moderate (>25-50%), or high (≤25%).

Outcome measurement

The primary outcomes of this systematic review and meta-analysis were Mpox severity and CFR. The secondary outcomes included the vaccination uptake and the clinical manifestations among suspected and confirmed cases. Mpox severity rate was determined by calculating the proportion of participants exhibiting severe or grave clinical manifestations of Mpox out of the total number of confirmed cases. CFR was calculated by dividing the number of deaths observed within the population of suspected or confirmed cases. The Mpox vaccination uptake rate/coverage was obtained by dividing the total number of people who received the vaccine by the number of eligible participants. The frequency of each clinical manifestation was computed by dividing the number of events of each reported symptom or observed sign by the number of suspected or confirmed cases.

Operational definition

A suspected monkeypox case was defined as an individual presenting with a vesicular or pustular rash characterized by deep-seated, firm pustules, and at least one of the following symptoms: fever preceding the eruption, lymphadenopathy (inguinal, axillary, or cervical), or pustules or crusts on the palms of the hands or soles of the feet. A case was defined as laboratory-confirmed Mpox if at least one specimen yielded a positive result in the *Orthopoxvirus*-specific assay, Mpox-specific real-time polymerase chained reaction, or Mpox in culture [26,27]. Cases were classified as severe or grave (requiring hospitalization) if one or more of the following were present: extensive lesions (>100), hemorrhagic or pustular lesions, mucosal involvement (oral, genital, conjunctival), or systemic complications. Systemic complications included high fever (>39°C), altered general state (bedridden),

sepsis, encephalitis, secondary bacterial infections, hypotension, septic shock, severe dehydration, and keratitis potentially leading to corneal scarring and blindness [5,26,28]. Vaccination uptake refers to individuals who declared having received an Mpox vaccine or presented an Mpox vaccination card or a scar characteristic of smallpox vaccine injection [15,29].

Statistical analysis and synthesis

The I^2 statistic was used to assess heterogeneity of pooled estimates between studies. It was categorized as low (<25%), moderate (25−75%), or high (>75%). Subgroup analyses were conducted for temporal trends (study period), geographical disparities (study location), and disease burden. The disease burden cutoff was set based on the median of suspected or confirmed cases reported across included studies. A fixed-effect model was used when heterogeneity was <50%. Timeframes for this analysis were defined based on the global outbreak that led to a heightened global response [30]. A p-value of <0.05 was considered significant. All analyses were performed using the 'meta' package in R Statistics version 4.4.2 [31].

Publication bias and sensitivity test

A visual analysis using funnel plot was carried out to assess publication bias. Absence of publication bias was assumed based on observed symmetry of the inverted funnel shape. To further investigate potential bias, Egger's regression and Begg's rank correlation tests were performed. Sensitivity analysis was conducted by iteratively excluding one study at a time to assess the robustness of the pooled estimate.

Results

From an initial search yielding 454 records (445 online, 9 from other sources), we removed 16 duplicates and screened the remaining 438 by title/abstract and full text. Fifteen studies met our inclusion criteria and were analyzed (Fig. 1).

Studies selection

Fig. 1 PRISMA diagram flow from study identification to inclusion in the meta-analysis

Characteristic of reports included

A comprehensive analysis included 15 studies. Those reports findings dated back from 1984 to 2023 and involved population from community and hospital settings. The studies were conducted nationally or in various regions from CAR including the Region 2, 4 and 6. All studies used surveillance and investigation methodology (case series or case report) for data collection and a non-probabilistic sampling technique (Additional File 1, Supplementary Table 1)

Disease severity among confirmed Mpox cases

The overall pooled Mpox severity rate among confirmed cases was 60.92% (95% confidence interval (CI): 47.54-72.83; I^2 = 9.7% and p = 0.351) (Fig. 2).

Fig. 2 Pooled severity rate of Mpox cases in CAR

The subgroup analysis according to the study period revealed a non-significant decrease in Mpox severity rate from 66.00% (95% CI: 51.95-77.70; n = 4 studies) before 2022 to 42.86 (95% CI: 17.66-71.14; n = 1 study). The highest severity rate was observed in Region 6 (77.27%; 95% CI: 55.64-90.21; n = 2 studies), however there was no significant difference between severity rate across regions. Sites with highest notification of confirmed Mpox cases (12+) exhibited highest severity rate (61.54%; 95% CI: 47.78-73.67; n = 3 studies) (Table 1 and Additional Files 2, Supplementary Fig. 1-4).

Table 1 Subgroup meta-analysis of confirmed Mpox severity rate pooled estimates in CAR

Subgroup	Confirmed cases	Event rate[1] (%)	95% CI limits [1]		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2(%)	p-value
Period [2]							
☐ 2022	50	66.00	51.95	77.70	4	0	0.630
2022+	14	42.86	17.66	71.14	1	-	-
Region							
Region 2	14	42.86	17.66	71.14	1	-	-
Region 4	26	61.54	40.57	79.77	1	-	-
Region 6	22	77.27	55.64	90.21	2	0	0.463
Not specified	2	0.00	0.00	84.19	1	-	-
Participant							
General population	54	59.26	45.81	71.45	4	26.6	0.252
General population and HCW	10	70	34.75	93.33	1	-	-
Disease burden (confirmed cases)							
☐ 12	12	58.33	30.76	81.52	2	0	0.999
12+	52	61.54	47.78	73.67	3	51.1	0.130

[1]Fixed effects model; CI: Confidence interval; [2]Period before and after the 2022 global outbreak; HCW: Healthcare worker

Mortality among confirmed Mpox cases

The pooled CFR among confirmed Mpox cases was 10.87% (95% CI: 5.95-19.04; I^2 = 0.0% and p = 0.879) (Fig. 3).

Fig. 3 Pooled case fatality rate among confirmed Mpox cases in CAR

The subgroup analysis revealed a non-significant decrease in CFR from 11.54%; (95% CI: 6.11-20.71; n = 9 studies) before 2022 to 7.14% (95% CI: 0.66-1.90; n = 13 studies) from 2022 on. The geographical trend highlighted higher mortality was recorded in Eastern Health Regions (11.11%; 95% CI: 5.08-22.60; n = 4 studies) and the lowest in Western Health Regions with no reported death (0.00%; 95% CI: 0.00-100.00; n = 2 studies). The CFR was increased with the burden of the disease. In areas reporting more than 8 suspected cases, the pooled CFR was 13.51% (95% CI: 7.43-23.33) (Table 2 and Additional Files 3, Supplementary Fig. 1-4).

Table 2 Subgroup meta-analysis of confirmed Mpox case fatality rate pooled estimates in CAR

Subgroup	Suspected cases	Event rate[1] (%)	95% CI limits [1]		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2(%)	p-value
Period [2]							
□ 2022	78	11.54	6.11	20.71	9	0	0.894
2022+	14	7.14	5.95	19.04	1	-	-
Region							
Western	8	0.00	0.00	100.00	2	0	1.000
Eastern	54	11.11	5.08	22.60	4	5	0.368
Multicentric/National	26	15.38	5.90	34.54	2	0	0.235
Not specified	4	0.00	0.00	100.00	2	-	-
Participant							
General population	82	9.76	4.95	18.31	9	0	0.809
General population and HCW	10	20.00	2.52	55.61	1	-	-
Disease burden (confirmed cases)							
□ 10	18	0.00	0.00	100.00	5	0	1.000
10+	74	13.51	7.43	23.33	5	12.8	0.332

Mortality among suspected Mpox cases

The pooled CFR among suspected Mpox cases was 10.71% (95% CI: 6.56-17.01; I^2 = 0.0% and p = 0.956) (Fig. 4).

Fig. 4 Pooled case fatality rate among suspected Mpox cases in CAR

The subgroup analysis revealed a slight decrease in CFR among suspected Mpox cases from 11.30% (95% CI: 6.68-18.50; n = 13 studies) before 2022 to 10.71% (95% CI: 6.56-17.01; n = 2 studies) from 2022 on. The Eastern Health Regions still exhibited higher CFR (9.30%; 95% CI: 4.72-17.51; n = 7 studies) compared to the Western Health Region (4.17%, 95% CI: 0.58-24.35; n = 4 studies). Localities with high burden of suspected cases (10+) presented higher CFR (11.43%, 95% CI: 6.61-19.05, n = 7 studies) (Table 3 and Additional Files 4, Supplementary Fig. 1-4).

Table 3 Subgroup meta-analysis of suspected Mpox case fatality rate pooled estimates in CAR

Subgroup	Suspected cases	Event rate[1] (%)	95% CI limits [1]		Number of studies	Heterogeneity statistic[1]	
			Lower	Upper		I^2(%)	*p*-value
Period [2]							
⬚ 2022	115	11.30	6.68	18.50	13	0	0.946
2022+	25	10.71	6.56	17.01	2	0	0.859
Region 1							
Region 1	7	0.00	0.00	100.00	2	0	1.000
Region 2	17	5.88	0.82	32.03	2	0	0.999
Region 4	35	2.86	0.40	17.68	2	0	0.999
Region 5	3	33.33	0.84	90.57	1	-	-
Region 6	48	12.50	5.73	25.15	4	0	0.641
Multicentric	12	25.00	5.49	57.19	1	-	-
National	14	7.14	0.18	33.87	1	-	-
Not specified	4	50.00	12.35	87.65	2	0	0.999
Region 2							
Western	24	4.17	0.58	24.35	4	0	1.000
Eastern	86	9.30	4.72	17.51	7	0	0.606
Multicentric/National	26	15.38	5.90	34.54	2	29.2	0.235
Not specified	4	50.00	12.35	87.65	2	0	0.999
Participant							
General population	125	10.40	6.14	17.09	14	0	0.932
General population and HCW	15	13.33	1.66	40.46	1	-	-
Disease burden (suspected cases)							
⬚ 10	35	8.57	2.79	23.44	8	0	1.000
10+	140	11.43	6.61	19.05	7	0	0.472

[1]Fixed effects model; CI: Confidence interval; [2]Period before and after the 2022 global outbreak; Western = Health Regions 1 and 2; Eastern = Health Regions 4, 5, and 6; HCW: Healthcare worker

Mpox vaccine uptake

The pooled vaccination uptake estimate was 20.00% (95% CI: 10.33-35.17) in CAR (Fig. 6)

Fig. 5 Pooled Mpox vaccination uptake rate in CAR

Mpox clinical pattern

The most reported clinical manifestations associated with confirmed Mpox disease included Fever, Chills or sweat, light sensitivity, and rash with pooled frequencies varying from 91.05 to 85.53% of cases (Table 4 and Fig. 7).

Table 4 Clinical patterns of confirmed Mpox cases in CAR

Rank	Clinical manifestation	Confirmed cases examined (n)	Frequency (%)	95% CI Limits		k	Heterogeneity statistic		Model
				Lower	Upper		I^2 (%)	p-value	
1	Fever	70	91.05	42.88	99.28	5	74.1	0.004	Random
2	Chills or sweat	10	90.00	55.50	99.75	1	-	-	-
3	Light sensitivity	9	88.89	51.75	99.72	1	-	-	-
4	Rash	76	85.53	75.72	91.80	6	15.8	0.312	Fixed
5	Oral lesions	20	59.16	8.56	95.73	2	86.5	0.007	Random
6	Pruritus or itchy lesion	46	58.57	31.53	81.27	3	59.1	0.087	Random
7	Genital lesions	19	57.43	8.76	94.99	2	85.4	0.009	Random
8	Lymphadenopathy	58	57.00	34.27	77.12	4	57.2	0.072	Random
9	Fatigue or asthenia	20	55.00	33.62	74.68	2	0.0	0.999	Fixed
10	Palm lesions	20	50.00	3.03	96.97	2	88.5	0.003	Random
11	Sole lesions	19	48.36	3.12	96.46	2	87.8	0.004	Random
12	Lesions	12	41.67	15.17	72.33	1	-	-	-
13	Headache	45	39.22	7.56	83.58	3	78.5	0.010	Random
14	Sore throat or dysphagia	35	37.87	11.67	73.76	2	83.5	0.014	Random
15	Myalgia	45	37.78	24.94	52.59	3	0.0	0.5770	Fixed
16	Cough	36	34.18	5.91	81.10	2	89.7	0.002	Random
17	Conjunctivitis	20	31.14	6.38	75.00	2	77.4	0.035	Random
18	Hemorrhagic skin lesions	9	22.22	2.81	60.01	1	-	-	-
19	Bedridden status	10	20.00	2.52	55.61	1	-	-	-
20	Vomiting or nausea	10	20.00	2.52	55.61	1	-	-	-
21	Diarrhea	9	11.11	0.28	48.25	1	-	-	-
22	Dyspnea	10	10.00	0.25	44.50	1	-	-	-
23	Facial oedema	10	10.00	0.25	44.50	1	-	-	-
24	Hypothermia	10	10.00	0.25	44.50	1	-	-	-

k = Number of studies; CI: Confidence interval;

Fig. 6 Clinical profile of confirmed Mpox cases in CAR

Publication bias and sensitivity test analysis

A large inverted symmetrical distribution of data points was observed on the funnel plot for the four outcomes assessed, suggesting a low risk of publication bias for all the outcome interest. In addition, the Egger's linear regression and Begg's rank correlation tests confirmed the absence of statistically significant publication bias for the CFR among suspected cases (Additional Files 2, Supplementary Fig. 5; Additional Files 3, Supplementary Fig. 6; Additional Files 4, Supplementary Fig. 5; and Additional File 5 Supplementary Fig. 1).

Sensitivity analysis, assessing the impact of individual studies and outliers on the overall results, demonstrated that no study exhibited a significant impact on the overall pooled estimate (Additional Files 2, Supplementary Fig. 6; Additional Files 3, Supplementary Fig. 7; and Additional Files 4, Supplementary Fig. 6).

Discussion

This in-depth systematic analysis and meta-analysis involved a comprehensive synthesis of 15 studies conducted in CAR between 1984 and 2023. These results provide critical insights into the epidemiological, clinical, and public health patterns of the Mpox virus in CAR.

Case fatality and clinical severity

In this study, an observed CFR of 10.87% was reported. This is markedly higher than figures reported in recent global outbreaks, where most studies reported CFR to remain consistently below 1%[32–34]. This high CFR is similar to earlier studies from the Democratic Republic of Congo (DRC), where surveillance between 2001 and 2013 revealed CFRs ranging from 6% to 10.6%, particularly in children and unvaccinated individuals [35,36]. Furthermore, similar mortality rates were documented in the CAR during earlier outbreaks in the 1980s [37]. The high CFR in CAR can be attributed to factors such as the endemic circulation of the more virulent clade I Mpox virus among CAR cases, limited healthcare access, poor health-seeking behavior, and frequent delays in case detection and isolation, especially in rural communities. This highlights the need for collaborative and resilient healthcare systems to reduce this mortality.

Notably, our analysis showed significantly higher CFRs in the Eastern Health Regions (9.30%; 95% CI: 4.72–17.51) compared to the Western Regions (4.17%; 95% CI: 0.58–24.35), with elevated mortality particularly concentrated in localities reporting a higher burden of suspected cases. These areas overlap with regions most affected by the prolonged conflict following the 2013 arm conflict, such as Haute-Kotto, Vakaga, Mbomou, and Ouham [38]. These zones have experienced repeated armed violence, mass displacement, and targeted attacks on health facilities, severely compromising access to healthcare services. Médecins Sans Frontières and other humanitarian agencies have reported recurrent looting, destruction of infrastructure, and withdrawal of essential health services in conflict-affected health districts such as Batangafo, Bambari, and Bangassou [39]. The ongoing insecurity continues to restrict healthcare workers' mobility and disrupt medical supply chains, further impeding timely diagnosis, isolation, and treatment of Mpox cases.

These conflict-driven vulnerabilities likely contribute significantly to the elevated mortality and underscore the urgent need for collaborative and resilient healthcare systems that can operate effectively amid political instability and violence to reduce Mpox-related deaths in CAR.

The Central African Republic's extensive border with the Democratic Republic of Congo (DRC) - the regional epicenter of Mpox - represents a critical transmission risk, particularly in Health Region 6 where the highest disease severity rate was documented. This border region's dense forest ecosystems and local populations' dependence on hunting, gathering, and agricultural activities create frequent human-animal interactions that facilitate zoonotic spillover [40]. The combination of cross-border movement and traditional livelihoods in these forested zones likely explains the elevated Mpox transmission observed in these communities and subsequent likelihood of high severity in this setting.

About 61% of cases with clinical severity in CAR reported systems such as fever (91%), rash (86%), photophobia (89%), and fatigue (55%). These presentations are consistent with earlier descriptions of Clade I infections, which are known to be responsible for systemic illness with complications such as secondary bacterial infections, dehydration, and acute respiratory distress[36,41]. The WHO has previously characterized Clade I as causing more severe and widespread disease, with a higher propensity for complications and mortality compared to Clade IIa or IIb [42].

On the other hand, the 2022–2023 Mpox outbreaks, predominantly caused by Clade IIb, presented with milder disease profiles. An extensive multinational cohort study across 16 countries by Thornhill *et al.* found that most patients exhibited localized anogenital lesions with minimal systemic symptoms, and hospitalization was required in less than 10% of cases [33]. Similarly, Tarín-Vicente et al [32] observed that although pain was a common symptom, especially with perianal lesions, life-threatening complications were rare, and the CFR was negligible. This phenotypic difference reflects both virological differences and contextual health infrastructure disparities across many countries, especially in Africa, where timely access to quality and affordable healthcare remains limited in most countries.

Another major challenge in CAR is underreporting, which underestimates the actual burden of Mpox reported over the years. Rural communities often lack access to quality healthcare, including diagnostic testing and trained personnel. Studies have highlighted that several cases may go undetected for every confirmed Mpox case in endemic areas due to inadequate surveillance [43].

Moreover, symptoms of Mpox can overlap with other endemic conditions like varicella, measles, or bacterial skin infections, leading to misclassification and diagnostic delays [44]. The low testing and reporting rates hinder effective outbreak response, delay contact tracing, and impair understanding of virus evolution.

On the other hand, during recent outbreaks, a number of African nations have shown successful testing and reporting techniques. For example, Nigeria expanded molecular diagnostics through the Nigeria Centre for Disease Control during the 2022–2023 mpox outbreak, allowing for weekly situation reporting and prompt case confirmation [45]. Similarly, real-time reporting and trend monitoring of monkeypox have been enhanced in the Democratic Republic of the Congo through the implementation of surveillance technologies such as DHIS2 and systematic case notification [46].

Vaccination access and global inequity

The review showed a low vaccination uptake in CAR (20%). These results corroborates finding from the neighboring DRC [35]. This could be due to supply limitations, healthcare infrastructural challenges, and vaccine hesitancy among the population. Historically, smallpox vaccination provided cross-protection against Mpox, with immunity estimates around 85% [48]. However, the cessation of global smallpox immunization in 1980 resulted in a growing cohort of susceptible individuals in endemic regions [49]. Countries like CAR, with weak immunization infrastructure, have since lacked routine smallpox-derived protection and access to new Mpox-specific vaccines.

In contrast, during the 2022 outbreak, developed countries rapidly deployed targeted vaccination campaigns. For example, the U.S. administered over 1.2 million doses of JYNNEOS by early 2023 [50], prioritizing healthcare workers and most vulnerable groups like men who have sex with men. Similarly, the UK initiated a pre-exposure prophylaxis campaign using a ring vaccination strategy [51]. These discrepancies showed broader global health inequities in global vaccine distribution efforts and research funding towards endemic countries like CAR, which the Mpox morbidity and mortality have impacted for decades.

Strength and limitations

This review has several limitations. First, some death cases might have been unreported due to study design, potentially underestimating the true CFR. Confounding by strain differences remains a concern, as the lack of comprehensive genomic data in many studies obscures the clade-specific

mortality rates. Surveillance bias, particularly the potential for improved detection of milder cases in more recent studies, may also influence the CFR estimates. Additionally, the small sample sizes in some subgroup analyses result in wide confidence intervals, limiting the precision of the findings. The database like CINAHL, Embase were not included in data search and study in other language than English and French were not searched. Despite these limitations, this systematic review and meta-analysis provides valuable insights into Mpox severity and mortality in the CAR. The findings highlight the continued public health importance of Mpox in the region and underscore the need for ongoing surveillance, research, and interventions to reduce the burden of this disease.

Conclusions

Mpox remains a major public health challenge in the Central African Republic, with mortality and disease severity far exceeding those reported in recent non-endemic outbreaks. This disparity is primarily due to the circulation of the more virulent Clade I virus and also reflects limited healthcare access, low vaccination coverage, and underinvestment in surveillance infrastructure. Future research in the country should explore and confirm these gaps in the management of Mpox cases. Consequently, the international response to Mpox must address these structural inequities through enhanced resource allocation, targeted vaccine delivery, community education, healthcare worker training, and research partnerships with endemic countries.

Abbreviations

CAR: Central African Republic

CFR: Case Fatality Rate

CI: Confidence Interval

DRC: Democratic Republic of Congo

HCW: Healthcare worker

MeSH: Medical Subject Headings

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis

WHO: World Health Organization

Declarations

Author contributions: F.Z.L.C. conceived the original idea of the study; F.Z.L.C. and C.A. conducted the literature search; F.Z.L.C., D.R.T. and L.B.K.B. selected the studies, extracted the relevant information, and synthesized the data. F.Z.L.C. performed the analyses and wrote the first draft of the manuscript. All authors critically reviewed and revised successive drafts of the manuscript. All authors read and approved of the final manuscript.

Ethical approval statement: Not applicable

Consent for publication: Not applicable.

Availability of data and materials: The sources of data supporting this systematic review are available in the reference. All data generated or analyzed during this study are included in this published article and supplemental material.

Competing interests: All authors declare no conflicts of interest and have approved of the final version of the article.

Funding source: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

References

1. Ebede SO, Orabueze IN, Maduakor UC, Nwafia IN, Ohanu ME. Recurrent Mpox: divergent virulent clades and the urgent need for strategic measures including novel vaccine development to sustain global health security. BMC Infect Dis. 2025;25(1):536.

2. First meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024. WHO, Geneva. 2024. https://www.who.int/news/item/19-08-2024-first-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-upsurge-of-mpox-2024. Accessed 2025 Jul 1.

3. Multi-country outbreak of mpox, External situation report #53 - 29 May 2025. WHO, Geneva. 2025. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--53---29-may-2025. Accessed 2025 Jul 1.

4.   Clade I Mpox Outbreak Originating in Central Africa. CDC, Atlanta. 2025. https://www.cdc.gov/mpox/outbreaks/2023/index.html. Accessed 2025 Jul 1.

5.   Cheuyem FZL, Zemsi A, Ndungo JH, Achangwa C, Takpando-le-grand DR, Goupeyou-Youmsi J, et al. Mpox severity and mortality in the most endemic focus in africa: a systematic review and meta-analysis (1970-2024). medRxiv; 2025. doi:10.1101/2025.04.07.25325410v2.

6.   Africa CDC Declares Mpox A Public Health Emergency of Continental Security, Mobilizing Resources Across the Continent. Africa CDC, Adis Abeba. 2024. https://africacdc.org/news-item/africa-cdc-declares-mpox-a-public-health-emergency-of-continental-security-mobilizing-resources-across-the-continent/. Accessed 2025 Jul 1.

7.   Mpox in the United States and Around the World: Current Situation. CDC, Atlanta. 2025. Available from: https://www.cdc.gov/mpox/situation-summary/index.html. Accessed 2025 Jul 1.

8.   Besombes C, Mbrenga F, Malaka C, Gonofio E, Schaeffer L, Konamna X, et al. Investigation of a mpox outbreak in Central African Republic, 2021-2022. One Health. 2023; 16:100523.

9.   Africa CDC and WHO update mpox strategy as outbreaks persist. 2025. https://www.who.int/news/item/17-04-2025-africa-cdc-and-who-update-mpox-strategy-as-outbreaks-persist. Accessed 2025 Jul 1.

10.   Mpox Preparedness and Response Plan for Africa 2025 | Global Crisis Response Platform. OIM, Geneva. 2024. Available from: https://crisisresponse.iom.int/response/mpox-preparedness-and-response-plan-africa-2025. Accessed 2025 Jul 1.

11.   Kostandova N, OKeeffe J, Ali BB, Somsé P, Mahieu A, Bingou OG, et al. "It's normal to be afraid": attacks on healthcare in Ouaka, Haute-Kotto, and Vakaga prefectures of the Central African Republic, 2016–2020. Confl Health. 2024;18(1):54.

12.   Gang KBA, O'Keeffe J, Anonymous, Roberts L. Cross-sectional survey in Central African Republic finds mortality 4-times higher than UN statistics: how can we not know the Central African Republic is in such an acute humanitarian crisis? Confl Health. 2023;17(1):21.

13.   Liu E, Sun L. 32. Protecting the vulnerable. Infect Dis Emergencies. 2025; Available from: https://emergencies.pubpub.org/pub/protecting-the-vulnerable/release/4. Accessed 2025 Jul 1.

14.   Tosam MJ, Ambe JR, Chi PC. Global Emerging Pathogens, Poverty and Vulnerability: An Ethical Analysis. Socio-Cult Dimens Emerg Infect Dis Afr. 2019 ;243–53.

15.   Cheuyem FZL, Amani A, Umar AA, Achangwa C, Ajong BN, Dabou S, et al. Mpox vaccine uptake in the most endemic focus in Africa: a systematic review and meta-analysis (1970–2024). *medRxiv*; 2025. doi:10.1101/2025.05.23.25327865v1.

16.   Du M, Deng J, Yan W, Liu M, Liang W, Niu B, et al. Mpox vaccination hesitancy, previous immunisation coverage, and vaccination readiness in the African region: a multinational survey. eClinicalMedicine. 2025; 80:103047.

17.   Nakoune E, Lampaert E, Ndjapou SG, Janssens C, Zuniga I, Van Herp M, et al. A Nosocomial Outbreak of Human Monkeypox in the Central African Republic. Open Forum Infect Dis. 2017;4(4): ofx168.

18.   Berthet N, Nakouné E, Whist E, Selekon B, Burguière AM, Manuguerra JC, et al. Maculopapular lesions in the Central African Republic. The Lancet. 2011;378(9799):1354.

19.   Kalthan E, Dondo-Fongbia JP, Yambele S, Dieu-Creer LR, Zepio R, Pamatika CM. Epidémie de 12 cas de maladie à virus monkeypox dans le district de Bangassou en République Centrafricaine en décembre 2015. Bull Société Pathol Exot. 2016;109(5):358–63.

20.   Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med. 2009;6(7): e1000097.

21.   Central African Republic Population (1950-2025). Macrotrend. Available from: https://www.macrotrends.net/global-metrics/countries/caf/central-african-republic/population. Accessed 2025 Jul 1.

22.   République Centrafricaine - Vue d'ensemble. Banque Mondial, Bangui, RCA. Available from: https://www.banquemondiale.org/fr/country/centralafricanrepublic/overview. Accessed 2023 Dec 1.

23.   Ministère de la Santé et de la Population-RCA. Plan National de Développement Sanitaire (PNDS III) 2022-2026. 2022.

24. Cheuyem FZL, Zombré D, Banthas-Bata GG, Lalani A, Yaman A, Romano S, et al. Using A Multi-Criteria Method for the Recruitment and Deployment of Health Human Resources to Strengthen the Health System in Central African Republic. Research Square; 2024.doi: 10.21203/rs.3.rs-5419097/v1.

25. JBI Critical Appraisal Tools. The Joanna Briggs Institute, Adelaide. 2017. Available from: https://jbi.global/critical-appraisal-tools. Accessed 2024 Dec 3.

26. Whitehouse ER, Bonwitt J, Hughes CM, Lushima RS, Likafi T, Nguete B, et al. Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011–2015. J Infect Dis. 2021;223(11):1870–8.

27. Cheuyem FZL, Asahngwa C, Bakari WN, Achangwa C, Goupeyou-Youmsi J, Ajong BN, et al. Mpox clinical features and varicella-zoster virus coinfection in the Democratic Republic of Congo: a systematic review and meta-analysis (1970-2024). medRxiv; 2025. doi:10.1101/2025.05.02.25326902v1.

28. Breman JG, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165.

29. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593–7.

30. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. N Engl J Med. 2022;387(8):679–91.

31. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2024. Available from: https://www.R-project.org/. Accessed 2024 Dec 19.

32. Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. The Lancet. 2022;400(10353):661–9.

33. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. N Engl J Med. 2022;387(8):679–91.

34. CDC. Mpox in the United States and Around the World: Current Situation. Mpox. 2025. https://www.cdc.gov/mpox/situation-summary/index.html. Accessed 2025 Jul 2.

35. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16262–7.

36. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis. 2006;194(6):773–80.

37. Jezek Z, Grab B, Szczeniowski M, Paluku KM, Mutombo M. Clinico-epidemiological features of monkeypox patients with an animal or human source of infection. Bull World Health Organ. 1988;66(4):459–64.

38. Central African Republic: Humanitarian Needs and Response Plan (December 2024) | OCHA. 2024. Available from: https://www.unocha.org/publications/report/central-african-republic/central-african-republic-humanitarian-needs-and-response-plan-december-2024. Accessed 2025 Jul 7.

39. Central African Republic: Repeated attacks on medical care leave people vulnerable to disease and death | MSF Eastern Africa. Doctors Without Borders | MSF Eastern Africa. Available from: https://msf.or.ke/news-and-resources/latest-news/central-african-republic-repeated-attacks-medical-care-leave-people. Accessed 2025 Jul 7.

40. Doty J, Malekani J, Kalemba L, Stanley W, Monroe B, Nakazawa Y, et al. Assessing Monkeypox Virus Prevalence in Small Mammals at the Human–Animal Interface in the Democratic Republic of the Congo. Viruses. 2017;9(10):283.

41. Berthet N, Nakouné E, Whist E, Selekon B, Burguière AM, Manuguerra JC, et al. Maculopapular lesions in the Central African Republic. Lancet Lond Engl. 2011 Oct 8;378(9799):1354.

42. Mpox. WHO Geneva.2024. https://www.who.int/news-room/fact-sheets/detail/mpox. Accessed 2025 Jul 2.

43. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019 Oct 16;13(10): e0007791.

44. Philpott D, Hughes CM, Alroy KA, Kerins JL, Pavlick J, Asbel L, et al. Epidemiologic and Clinical Characteristics of Monkeypox Cases - United States, May 17-July 22, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(32):1018–22.

45. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019 ;19(8) :872–9.

46. Bangwen E, Diavita R, Vos ED, Vakaniaki EH, Nundu SS, Mutombo A, et al. Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of national epidemiological and laboratory surveillance data, 2010–23. The Lancet. 2025;405(10476):408–19.

47. Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022;28(8):1569–72.

48. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988;17(3):643–50.

49. Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017-2020. Emerg Infect Dis. 2021;27(4):1007–14.

50. CDC. Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States. Mpox. 2025. https://www.cdc.gov/mpox/hcp/vaccine-considerations/vaccination-overview.html. Accessed 2025 Jul 2.

51. Mpox: background information. GOV.UK. 2025. https://www.gov.uk/guidance/monkeypox. Accessed 2025 Jul 2.